Evaluating the efficacy of ursobil in reducing bilirubi
Phase 1
- Conditions
- neonatal jaundice.Neonatal jaundice from other and unspecified causes
- Registration Number
- IRCT201701313915N18
- Lead Sponsor
- Research vice chancellor of Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
Birth weight more than 2500 grams; gestation age more than 35 weeks; age above 3 days less than 2 weeks; total serum bilirubin 14-20 mg/dl; direct bilirubin less than 2 mg/dl.
Exclusion criteria:
ABO incompatibility; Rh immunization; G6PDdefficiency; direct hyperbilirubinemia; sepsis; Crigler-Najjar syndrome; thyroid disorders; hepatic diseases; prematurity; infant of diabetic mother
.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The rate of bilirubin decrease. Timepoint: 6,12,24 and 48 hours after starting treatment. Method of measurement: Measurment of total serum bilirubin.
- Secondary Outcome Measures
Name Time Method The duration of hospitalization. Timepoint: From admission til discharge. Method of measurement: The hours and days of admission.